The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: A randomized controlled study

Human Brain Mapping

Volumn 37, Issue 3, 2016, Pages 1080-1090

  Li, Cheng Ta ^a,b   Chen, Mu Hong ^a,b   Lin, Wei Chen ^a,b   Hong, Chen Jee ^a,b   Yang, Bang Hung ^a   Liu, Ren Shyan ^a   Tu, Pei Chi ^a,b   Su, Tung Ping ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Glucose; Ketamine; Prefrontal cortex; Treatment resistant depression

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUTAMIC ACID; KETAMINE; SODIUM CHLORIDE; AMINO ACID RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; AMYGDALOID NUCLEUS; ANTIDEPRESSANT ACTIVITY; ARTICLE; BRAIN REGION; CHEST TIGHTNESS; CLINICAL ARTICLE; CONTROLLED STUDY; DIZZINESS; DSM-IV-TR; FEMALE; GLUCOSE METABOLISM; HAMILTON DEPRESSION RATING SCALE; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; MALE; NAUSEA; NEUROTRANSMISSION; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESISTANT DEPRESSION; AMYGDALA; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DIAGNOSTIC IMAGING; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; STATISTICAL MODEL;

ADULT; AMYGDALA; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; FLUORODEOXYGLUCOSE F18; GLUTAMIC ACID; HUMANS; KETAMINE; LINEAR MODELS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PSYCHIATRIC STATUS RATING SCALES; RADIOPHARMACEUTICALS;

EID: 84958236573     PISSN: 10659471     EISSN: 10970193     Source Type: Journal    
DOI: 10.1002/hbm.23085     Document Type: Article

References (40)

1. Arana AB, Borckardt JJ, Ricci R, Anderson B, Li X, Linder KJ, Long J, Sackeim HA, George MS (2008): Focal electrical stimulation as a sham control for repetitive transcranial magnetic stimulation: Does it truly mimic the cutaneous sensation and pain of active prefrontal repetitive transcranial magnetic stimulation? Brain Stimul 1:44-51.
2. Aroni F, Iacovidou N, Dontas I, Pourzitaki C, Xanthos T (2009): Pharmacological aspects and potential new clinical applications of ketamine: Reevaluation of an old drug. J Clin Pharmacol 49:957-964.
3. Beauregard M (2007): Mind does really matter: Evidence from neuroimaging studies of emotional self-regulation, psychotherapy, and placebo effect. Prog Neurobiol. 81:218-236.
4. Berlim MT, van den Eynde F, Tovar-Perdomo S, Daskalakis ZJ (2013): Response, remission and drop-out rates following high-frequency repetitive transcranial magnetic stimulation (rTMS) for treating major depression: A systematic review and meta-analysis of randomized, double-blind and sham-controlled trials. Psychol Med 1-15.
5. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000): Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351-354.
6. Borckardt JJ, Reeves ST, Weinstein M, Smith AR, Shelley N, Kozel FA, Nahas Z, Byrne KT, Morgan K, George MS (2008): Significant analgesic effects of one session of postoperative left prefrontal cortex repetitive transcranial magnetic stimulation: A replication study. Brain Stimul 1:122-127.
7. Breier A, Malhotra AK, Pinals DA, Weisenfeld NI, Pickar D (1997): Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry 154:805-811.
8. Buckalew LW, Coffield KE (1982): An investigation of drug expectancy as a function of capsule color and size and preparation form. J Clin Psychopharmacol 2:245-248.
9. De Ridder D, Vanneste S, Kovacs S, Sunaert S, Dom G (2011): Transient alcohol craving suppression by rTMS of dorsal anterior cingulate: An fMRI and LORETA EEG study. Neurosci Lett 496:5-10.
10. Fitzgerald PB, Oxley TJ, Laird AR, Kulkarni J, Egan GF, Daskalakis ZJ (2006): An analysis of functional neuroimaging studies of dorsolateral prefrontal cortical activity in depression. Psychiatry Res 148:33-45.
11. Gispert JD, Pascau J, Reig S, Martinez-Lazaro R, Molina V, Garcia-Barreno P, Desco M (2003): Influence of the normalization template on the outcome of statistical parametric mapping of PET scans. Neuroimage 19:601-612.
12. Graf T, Engeler J, Achermann P, Mosimann UP, Noss R, Fisch HU, Schlaepfer TE (2001): High frequency repetitive transcranial magnetic stimulation (rTMS) of the left dorsolateral cortex: EEG topography during waking and subsequent sleep. Psychiatry Res 107:1-9.
13. Hamilton M (1967): Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278-296.
14. Hirvonen J, Goodwin RS, Li CT, Terry GE, Zoghbi SS, Morse C, Pike VW, Volkow ND, Huestis MA, Innis RB (2012): Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Mol Psychiatry 17:642-649.
15. Holcomb HH, Lahti AC, Medoff DR, Weiler M, Tamminga CA (2001): Sequential regional cerebral blood flow brain scans using PET with H2(15)O demonstrate ketamine actions in CNS dynamically. Neuropsychopharmacology 25:165-172.
16. Jandl M, Bittner R, Sack A, Weber B, Gunther T, Pieschl D, Kaschka WP, Maurer K (2005): Changes in negative symptoms and EEG in schizophrenic patients after repetitive transcranial magnetic stimulation (rTMS): An open-label pilot study. J Neural Transm 112:955-967.
17. Katalinic N, Lai R, Somogyi A, Mitchell PB, Glue P, Loo CK (2013): Ketamine as a new treatment for depression: A review of its efficacy and adverse effects. Aust N Z J Psychiatry 47:710-727.
18. Kimbrell TA, Little JT, Dunn RT, Frye MA, Greenberg BD, Wassermann EM, Repella JD, Danielson AL, Willis MW, Benson BE, Speer AM, Osuch E, George MS, Post RM. (1999): Frequency dependence of antidepressant response to left prefrontal repetitive transcranial magnetic stimulation (rTMS) as a function of baseline cerebral glucose metabolism. Biol Psychiatry 46:1603-1613.
19. Kupfer DJ, Frank E, Phillips ML (2012): Major depressive disorder: New clinical, neurobiological, and treatment perspectives. Lancet 379:1045-1055.
20. Lally N, Nugent AC, Luckenbaugh DA, Ameli R, Roiser JP, Zarate CA (2014): Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Transl Psychiatry 4:e469.
21. Lally N, Nugent AC, Luckenbaugh DA, Niciu MJ, Roiser JP, Zarate CA Jr. (2015): Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. J Psychopharmacol 29:596-607.
22. Levinson AJ, Fitzgerald PB, Favalli G, Blumberger DM, Daigle M, Daskalakis ZJ (2010): Evidence of cortical inhibitory deficits in major depressive disorder. Biol Psychiatry 67:458-464.
23. Li CT, Lin CP, Chou KH, Chen IY, Hsieh JC, Wu CL, Lin WC, Su TP (2010a): Structural and cognitive deficits in remitting and non-remitting recurrent depression: A voxel-based morphometric study. Neuroimage 50:347-356.
24. Li CT, Wang SJ, Hirvonen J, Hsieh JC, Bai YM, Hong CJ, Liou YJ, Su TP (2010b): Antidepressant mechanism of add-on repetitive transcranial magnetic stimulation in medication-resistant depression using cerebral glucose metabolism. J Affect Disord 127:219-229.
25. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li XY, Aghajanian G, Duman RS (2010c): mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329:959-964.
26. Li CT, Su TP, Wang SJ, Tu PC, Hsieh JC (2015): Prefrontal glucose metabolism in medication-resistant major depression. Br J Psychiatry 206:316-323.
27. Magistretti PJ, Pellerin L (1999): Astrocytes Couple Synaptic Activity to Glucose Utilization in the Brain. News Physiol Sci 14:177-182.
28. Mathew SJ, Shah A, Lapidus K, Clark C, Jarun N, Ostermeyer B, Murrough JW (2012): Ketamine for treatment-resistant unipolar depression: Current evidence. CNS Drugs 26:189-204.
29. Mayberg HS, Liotti M, Brannan SK, McGinnis S, Mahurin RK, Jerabek PA, Silva JA, Tekell JL, Martin CC, Lancaster JL, Fox PT. (1999): Reciprocal limbic-cortical function and negative mood: Converging PET findings in depression and normal sadness. Am J Psychiatry 156:675-682.
30. Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, Iqbal S, Pillemer S, Foulkes A, Shah A, Charney DS, Mathew SJ. (2013): Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-site randomized controlled trial. Am J Psychiatry 170:1134-1142.
31. Naughton M, Clarke G, O'Leary OF, Cryan JF, Dinan TG (2014): A review of ketamine in affective disorders: Current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. J Affect Disord 156:24-35.
32. Nugent AC, Diazgranados N, Carlson PJ, Ibrahim L, Luckenbaugh DA, Brutsche N, Herscovitch P, Drevets WC, Zarate CA Jr. (2014): Neural correlates of rapid antidepressant response to ketamine in bipolar disorder. Bipolar Disord 16:119-128.
33. Overall JE, Gorham DR (1962): The brief psychiatric rating scale. Psychol Rep 10:799-812.
34. Paul IA, Skolnick P (2003): Glutamate and depression: Clinical and preclinical studies. Ann N Y Acad Sci 1003:250-272.
35. Petrovic P, Dietrich T, Fransson P, Andersson J, Carlsson K, Ingvar M (2005): Placebo in emotional processing-induced expectations of anxiety relief activate a generalized modulatory network. Neuron 46:957-969.
36. Price JL, Drevets WC (2010): Neurocircuitry of mood disorders. Neuropsychopharmacology 35:192-216.
37. Schutter DJ, van Honk J, d'Alfonso AA, Postma A, de Haan EH (2001): Effects of slow rTMS at the right dorsolateral prefrontal cortex on EEG asymmetry and mood. Neuroreport 12:445-447.
38. Signorini M, Paulesu E, Friston K, Perani D, Colleluori A, Lucignani G, Grassi F, Bettinardi V, Frackowiak RS, Fazio F (1999): Rapid assessment of regional cerebral metabolic abnormalities in single subjects with quantitative and nonquantitative [18F]FDG PET: A clinical validation of statistical parametric mapping. Neuroimage 9:63-80.
39. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, Mazoyer B, Joliot M (2002): Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 15:273-289.
40. Zarate CA, Jr., Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006): A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 63:856-864.